[HTML][HTML] Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future
AK Stueven, A Kayser, C Wetz, H Amthauer… - International journal of …, 2019 - mdpi.com
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased.
Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases …
Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases …
Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications
S Banerjee, MRA Pillai, FF Knapp - Chemical reviews, 2015 - ACS Publications
Interest in the use of radionuclides for treatment of various diseases has a long history and
parallels the isolation of radium by Marie and Pierre Curie in the early part of the 20th …
parallels the isolation of radium by Marie and Pierre Curie in the early part of the 20th …
The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors
JR Howe, NB Merchant, C Conrad, XM Keutgen… - Pancreas, 2020 - journals.lww.com
This manuscript is the result of the North American Neuroendocrine Tumor Society
consensus conference on the surgical management of pancreatic neuroendocrine tumors …
consensus conference on the surgical management of pancreatic neuroendocrine tumors …
The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors
This article is the result of the North American Neuroendocrine Tumor Society consensus
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic …
A Rinke, M Wittenberg, C Schade-Brittinger… - …, 2016 - karger.com
Background: Somatostatin analogs have been shown to control the growth of well-
differentiated metastatic neuroendocrine tumors. Their effect on overall survival is a matter of …
differentiated metastatic neuroendocrine tumors. Their effect on overall survival is a matter of …
[HTML][HTML] Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility …
U Garske-Román, M Sandström, K Fröss Baron… - European journal of …, 2018 - Springer
Purpose Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
L Bodei, MS Kidd, A Singh, WA van der Zwan… - European journal of …, 2020 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable
neuroendocrine tumors (NETs). Imaging response assessment is usually efficient …
neuroendocrine tumors (NETs). Imaging response assessment is usually efficient …
[HTML][HTML] Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER …
Purpose To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP)
elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate. Methods In …
elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate. Methods In …
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
L Bodei, MS Kidd, A Singh, WA Van Der Zwan… - European journal of …, 2018 - Springer
Background Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor
(SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy …
(SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy …
Radionuclide therapy for neuroendocrine tumors
M Cives, J Strosberg - Current oncology reports, 2017 - Springer
Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows
targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin …
targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin …